1. Home
  2. EPSM vs CNSY Comparison

EPSM vs CNSY Comparison

Compare EPSM & CNSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Epsium Enterprise Limited Ordinary Shares

EPSM

Epsium Enterprise Limited Ordinary Shares

HOLD

Current Price

$1.57

Market Cap

18.9M

Sector

N/A

ML Signal

HOLD

Logo Cerenome Inc. Common Stock

CNSY

Cerenome Inc. Common Stock

N/A

Current Price

$2.07

Market Cap

20.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EPSM
CNSY
Founded
2010
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9M
20.6M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
EPSM
CNSY
Price
$1.57
$2.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
726.7K
67.5K
Earning Date
04-29-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
87.61
EPS
N/A
N/A
Revenue
N/A
$5,213,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.83
$1.90
52 Week High
$42.45
$4.03

Technical Indicators

Market Signals
Indicator
EPSM
CNSY
Relative Strength Index (RSI) 61.73 23.86
Support Level $1.33 N/A
Resistance Level $1.59 $3.28
Average True Range (ATR) 0.14 0.18
MACD -0.00 -0.03
Stochastic Oscillator 50.14 11.30

Price Performance

Historical Comparison
EPSM
CNSY

About EPSM Epsium Enterprise Limited Ordinary Shares

Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohols.

About CNSY Cerenome Inc. Common Stock

Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.

Share on Social Networks: